Two sources describe a planned escalation of tariffs on imported generic medicines, with one reporting 100 percent duties from August 2028 and the other describing a zero-tariff period beginning August 2026 followed by 100 percent and then 200 percent rates. Both sources agree that tariffs would reach 200 percent after an initial 100 percent period. India is reported to supply nearly half of U.S. generic prescriptions, though manufacturing-location data conflict between the sources.